My strategy as a dividend growth investor is to buy qualitative stocks with an adequate margin of safety. My reasoning is two-pronged: First, this can limit downside risk if black swan events materialize. Second, this approach allows me to secure greater starting income and providesHi, my name is Kody. Aside from my articles here on Seeking Alpha, I am also a regular contributor to TipRanks, Sure Dividend, and The Dividend Kings and iREIT+Hoya Capital. I have been investing since September 2017 and interest ...

Company Overview - Amgen Inc is a biotechnology company with a strong track record in developing and commercializing products in four main therapeutic areas: general medicine, rare disease, oncology, and inflammation/immunology [1] - The company reported a 24% revenue growth in its Q3 2024 financial report [1] Analyst Background - The analyst has a background in life sciences with a PhD in Bioengineering and over 20 years of experience in research and development of novel Cell & Gene Therapies (CGT) [1] - The analyst focuses on analyzing biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging their expertise to assess the potential of novel treatments and their impact on shareholder returns [1] Disclosure and Position - The analyst holds a beneficial long position in Amgen Inc through stock ownership, options, or other derivatives [2] - The analyst wrote the article independently and is not receiving compensation for it other than from Seeking Alpha [2]

Blue poker chips on stock market chart backgroundgettyThe Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays. We’ll discuss individual Dogs—and their divvies—in a moment. First, the simple three-step strategy: Step 1: After the final trading day of the year, identify the 10 highest-yielding stocks in the Dow. Step 2: Buy all 10 stocks in equal amounts and hold them for a year. Step 3: At the end of the year, sell, then rinse and repeat.Why has ...

Amgen (AMGN) - Amgen's stock experienced a significant drop in late November due to phase 2 clinical trial results for its weight loss candidate, MariTide, which showed a 20% body weight loss after 52 weeks, below the expected 25% [2][3] - The market's reaction to the trial results is seen as an overreaction, creating a buying opportunity for investors who view MariTide as a promising treatment alternative to weekly injections from Eli Lilly and Novo Nordisk [4][5] - Amgen trades at 13 times forward earnings, offers a 3.6% yield, and is developing a GLP-1/GIPR combination treatment that could compete with Eli Lilly and Novo Nordisk [6] Eli Lilly (LLY) - Eli Lilly's shares have risen by 32% over the past year, with potential for further growth in 2025 due to multiple catalysts, including label expansions for tirzepatide (marketed as Zepbound and Mounjaro) for reducing type 2 diabetes risk [7] - Clinical readouts for tirzepatide in treating metabolic dysfunction-associated steatohepatitis and progress in other pipeline programs, such as retatrutide and orforglipron for weight loss, could drive the stock price [8][9] - The company's financial results are expected to remain strong, supported by the rapid sales growth of Zepbound and Mounjaro, as well as newer products like Kisunla for Alzheimer's, which received regulatory approval in July [10][11] Summit Therapeutics (SMMT) - Summit Therapeutics' stock surged by 583% in 2024, driven by positive phase 3 study results for ivonescimab in treating non-small cell lung cancer (NSCLC), conducted by its partner Akeso [12] - The company is expected to report results from its own late-stage study of ivonescimab in combination with chemotherapy as a second-line treatment for NSCLC, which could lead to regulatory approval [13] - Summit is also conducting a phase 3 study of ivonescimab in combination with chemotherapy as a first-line treatment for NSCLC and plans to initiate another late-stage study of the drug as a monotherapy in the first-line setting [15] - With a market cap of around $13.5 billion, positive late-stage results could significantly increase the company's valuation [16]

On Friday, Novo Nordisk A/S NVO released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without added side effects.Wil ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What a ...

The most recent trading session ended with Amgen (AMGN) standing at $273.41, reflecting a -0.85% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a gain of 0.82% for the day. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq gained 1.77%.Shares of the world's largest biotech drugmaker witnessed a loss of 7.73% over the previous month, trailing the performance of the Medical sector with its loss of 4.06% and the S&P 500's gain of 0.8%.Investo ...

The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Wall Street is chewing over critical data released last week on Amgen's experimental weight loss injection – a potential competitor in the blockbuster obesity drug market. Some analysts said the initial mid-stage trial result ...

Investment Establishes Second Facility in Holly Springs; Builds on Previous $550M Commitment THOUSAND OAKS, Calif., Dec. 5, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment. "This expansion underscores our unwavering focus on bringing transforma ...

The relationship between interest rates and dividend stocks tends to follow a predictable pattern. When the Federal Reserve signals a shift toward monetary easing, investors often rotate toward stable, high-yielding equities that can provide both income and potential appreciation.Amgen (AMGN -0.02%) offers an intriguing test case for this dynamic heading into 2025. The biotech-giant's shares have slumped 3.37% in 2024, while the S&P 500 has surged 26.8% as of this writing, creating what might be a compellin ...